Hiberix

Hiberix is a Haemophilus influenzae type b conjugate vaccine (tetanus toxoid conjugate) supplied as an injectable solution. It is a prescription‑only product marketed in the European Union and is administered intramuscularly or subcutaneously to stimulate active immunity against Hib infections in infants and young children.

Hiberix is indicated for the prevention of disease caused by Haemophilus influenzae type b. It is used in routine childhood immunization programs and may be given as part of a combination schedule with other pediatric vaccines.

- Primary immunization series for infants starting at 2 months of age - Booster doses to maintain protective antibody levels - Prevention of Hib meningitis, epiglottitis, pneumonia, and sepsis - Recommended for children at increased risk of Hib infection - May be used in catch‑up vaccination for children who missed earlier doses

Adverse reactions to Hiberix are generally mild and transient, but serious events can occur rarely.

Common: - Injection site pain, redness, or swelling - Low‑grade fever - Irritability or fussiness in infants - Mild rash or erythema - Headache - Fatigue

Serious: - Anaphylaxis or severe allergic reaction - Seizures (rare) - High‑grade fever persisting >24 hours - Persistent crying or inconsolable distress - Neurologic complications such as encephalopathy (extremely rare)

Before administering Hiberix, consider the following safety points:

- Verify no known severe allergy to any vaccine component, especially tetanus toxoid. - Defer vaccination in children with a moderate or severe acute illness. - Use caution in individuals with a history of seizures or neurological disorders. - Monitor for signs of an allergic reaction for at least 15 minutes after injection. - Discuss with a healthcare professional if the child is immunocompromised. - Pregnant or breastfeeding status should be evaluated by a clinician.

Hiberix may interact with other agents that affect immune response or increase the risk of adverse reactions.

Avoid: - Simultaneous administration of live bacterial vaccines at the same injection site. - Use of immunosuppressive therapy that could diminish vaccine efficacy.

Use with caution: - Concurrent administration of other injectable vaccines (schedule according to guidelines). - Antipyretics or analgesics taken prophylactically before vaccination. - Patients receiving blood products or immunoglobulins within 4 weeks of vaccination. - Children on high‑dose corticosteroids.